Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2024
Reporting Period: Fourth quarter and full year ended December 31, 2023
This filing serves as a notification that the Company issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2023. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release (Exhibit 99.1) but are not explicitly stated in the filing text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the fourth quarter and full year 2023.
Guidance, Outlook, and Risks
- Conference Call: The Company hosted a conference call on February 27, 2024, at 4:30 p.m. Eastern Time to present business and financial results. A webcast is archived on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
- Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and full-year 2023.
- Access the archived webcast on www.supernus.com for management commentary on the results.
- Consult the Form 10-K for the fiscal year ended December 31, 2022, for a comprehensive list of risk factors referenced in this filing.
- Verify the Company's liquidity position and debt levels in the detailed financial statements referenced in the press release.